Programa

MARTES 18 DE MAYO

14.30 h. Bienvenida y Presentación.

Speakers:

Dr. D. Pedro Peréz Segura

Oncología Médica-HCSC y Universidad Complutense Madrid.

Dr. D. Alberto Ocaña

Oncología Médica-HCSC y Universidad Castilla-La Mancha.

Dr. D. Guillermo Velasco Díez

Universidad Complutense Madrid.

15.00 h. Session 1. Novel Therapies and Multi-omics Approaches

Chairs:

Prof. D. Eduardo Díaz-Rubio

Real Academia Nacional de Medicina, Madrid.

Dr. D. Emiliano Calvo

Clara Campal, Madrid.

Speaker:

Dr. D. Alberto Ocaña

Oncología Médica-HCSC y Universidad Castilla-La Mancha.

15.00 h. Novel therapies and combinations on the horizon

Speaker:

Dr. D. Lajos Pusztai

Yale University, CT.

15.30 h. Identification of Novel Targets with Multi-omics and AI

Speaker:

Dª. María Muñoz Caffarel

Biodonostia

16.00 h. Targeting tumour-promoting inflammation in breast cancer

Speakers:

Prof. D. Eduardo Díaz-Rubio

Real Academia Nacional de Medicina, Madrid.

Dr. D. Emiliano Calvo

Clara Campal, Madrid.

Dr. D. Alberto Ocaña

Oncología Médica-HCSC y Universidad Castilla-La Mancha.

Dr. D. Lajos Pusztai

Yale University, CT.

Dª. María Muñoz Caffarel

Biodonostia

16.30 h. Discussion

17.00 h. Session 2. Breast Cancer and Novel Vulnerabilities

Chairs:

Dr. D. Atanasio Pandiella

CIC-Salamanca

Dr. D. José Ángel García Sáenz

HU Clínico San Carlos, Madrid.

Speaker:

Dr. D. Philippe Bedard

Princess Margaret Cancer Center. Toronto.

17.00 h. Targeting HER2 in Breast Cancer: novel opportunities

Speaker:

Dr. D. Miguel Martín Jiménez

Hospital Gregorio Marañón, Madrid .

17.30 h. Novel Opportunities in Triple Negative Breast Cancer

Speaker:

Dr. D. José Ángel García Sáenz

HU Clínico San Carlos, Madrid.

18.00 h. Strategies in Luminal Tumors

Speakers:

Dr. D. Atanasio Pandiella

CIC-Salamanca

Dr. D. José Ángel García Sáenz

HU Clínico San Carlos, Madrid.

Dr. D. Philippe Bedard

Princess Margaret Cancer Center. Toronto.

Dr. D. Miguel Martín Jiménez

Hospital Gregorio Marañón, Madrid .

18.30 h. Discussion

MIÉRCOLES 19 DE MAYO

15.00 h. Session 3. Ginecological Tumors and Melanoma

Chair:

Dr. D. Antonio Casado Herráez

Hospital Clínico San Carlos Madrid.

Speaker:

Dr. D. Antonio González Martín

CUN-Madrid.

15.00 h. Updates in Ovarian Cancer

Speaker:

Dr. D. Gennaro Ciliberto

Istituto Nazionale Tumori IRCCS.“Fondazione G. Pascale”, Naples, Italy; University of Catanzaro “Magna Graecia”, Catanzaro, Italy.

15.30 h. New Options in Melanoma

Speaker:

Dr. D. Jesús Paramio

Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) y Biomedical Research Institute I+12.

16.00 h. When Epigenetics met immunotherapy, A tale of bladder cáncer

Speakers:

Dr. D. Antonio Casado Herráez

Hospital Clínico San Carlos Madrid.

Dr. D. Jesús Paramio

Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) y Biomedical Research Institute I+12.

Dr. D. Antonio González Martín

CUN-Madrid.

Dr. D. Gennaro Ciliberto

Istituto Nazionale Tumori IRCCS.“Fondazione G. Pascale”, Naples, Italy; University of Catanzaro “Magna Graecia”, Catanzaro, Italy.

16.30 h. Discussion

17.00 h. Award of acknowledgement to the Scientific International Trajectory in Oncology (granted by the Scientific Committee and Fundación Cris contra el Cáncer)

17.15 h. Session 4. Urologic Cancer

Chairs:

Dr. D. Enrique Grande

Hospital MD Anderson. Madrid.

Dra. Dª. Verónica Torrano Moya

CiC Biogune.

Speaker:

Dr. D. Ian Tannock

UHN Toronto.

17.15 h. Novel Therapies in Prostate Cancer: lessons learned

Speaker:

Dr. D. Javier Puente Vázquez

Hospital Clínico San Carlos, Madrid.

17.45 h. Immunotherapies in Bladder Cancer

Speaker:

Dra. Dª. Verónica Torrano Moya

CiC Biogune.

18.15 h. Targeting PGC1α-driven transcriptional landscape for personalized

Speaker:

Dr. D. Francisco X. Real

CNIO. Madrid.

18.45 h. Bladder Cancer Subtypes: therapeutic implications

Speakers:

Dr. D. Enrique Grande

Hospital MD Anderson. Madrid.

Dra. Dª. Verónica Torrano Moya

CiC Biogune.

Dr. D. Ian Tannock

UHN Toronto.

Dr. D. Javier Puente Vázquez

Hospital Clínico San Carlos, Madrid.

Dr. D. Francisco X. Real

CNIO. Madrid.

19.15 h. Discussion

JUEVES 20 DE MAYO

15.00 h. Session 5. Lung Cancer and Traslational Oncology

Chairs:

Dra. Dª. Pilar Garrido

HU Ramón y Cajal, Madrid.

Dra. Dª. Patrizia Agostinis

University of Leuven.

Speaker:

Dr. D. Luis Montuenga Badía

CIMA, Pamplona.

15.00 h. Searching for novel targets in lung cancer. The potential of YES1

Speaker:

Dra. Dª. Enriqueta Felip

Vall D´Hebron, Barcelona.

15.30 h. Strategies After Progression

Speaker:

Dr. D. Luis Paz Ares

Hospital 12 Octubre, Madrid.

16.00 h. Novel Immunotherapies

Speaker:

Dra. Dª. Patrizia Agostinis

University of Leuven.

16.30 h. Targeting the tumor vasculature by harnessing autophagy

Speaker:

Dr. D. Guillermo Velasco Díez

Universidad Complutense Madrid.

17.00 h. Towards the utilization of cannabinoids as anticancer agents

Speakers:

Dra. Dª. Pilar Garrido

HU Ramón y Cajal, Madrid.

Dra. Dª. Patrizia Agostinis

University of Leuven.

Dr. D. Luis Montuenga Badía

CIMA, Pamplona.

Dra. Dª. Enriqueta Felip

Vall D´Hebron, Barcelona.

Dr. D. Luis Paz Ares

Hospital 12 Octubre, Madrid.

Dr. D. Guillermo Velasco Díez

Universidad Complutense Madrid.

17.30 h. Discussion

18.00 h. Keynote Lecture. “Kinase drug discovery 20 years after Imatinib: progress and future directions”

Chairs:

Dr. D. Guillermo Velasco Díez

Universidad Complutense Madrid.

Sir Philip Cohen

Dundee University.